Related Experiment Video
Updated: Jun 22, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The role of statin therapy in older adults: best practices and unmet challenges
John Stone1, Manish Kumar2, Ariela R Orkaby3
1Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Insights
Statin use for primary cardiovascular disease (CVD) prevention in adults 75+ is debated due to limited trial data. Current evidence suggests potential benefits for those without severe comorbidities, pending further research.
Area of Science:
- Geriatric Medicine
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) significantly impacts older adults' health and mortality.
- Current guidelines for statin use in primary CVD prevention for individuals aged 75 and older are conflicting.
- Older adults are often excluded from clinical trials, creating evidence gaps.
Purpose of the Study:
- To review current national and international guidelines on statin use for primary CVD prevention in older adults.
- To examine the evidence base informing these guidelines, considering age-related physiological changes.
- To discuss clinical considerations for statin therapy in this demographic.
Main Methods:
- A narrative review of literature using PubMed.
- Focus on seven major national and international lipid-lowering therapy guidelines.
- Analysis through two clinical case studies.
Main Results:
- Conflicting recommendations exist for statin use in primary CVD prevention for older adults.
- Evidence suggests statins may benefit older adults without significant comorbidities.
- Ongoing randomized controlled trials aim to resolve current evidence gaps.
Conclusions:
- The role of statins for primary CVD prevention in older adults requires further clarification.
- Individualized treatment decisions are crucial, considering patient comorbidities.
- Future research, including ongoing trials, will provide more definitive guidance.
Introduction:
Cardiovascular disease (CVD) is associated with significant morbidity, functional decline, and mortality in older adults. The role of statins for primary CVD prevention in older adults remains unclear, largely due to systematic exclusion of these individuals in trials that inform current practice guidelines, leading to conflicting national and international practice recommendations for statin use for primary prevention of CVD in adults aged 75 and older.
Areas Covered:
In this narrative review, we performed a literature review utilizing PubMed, and ultimately focus on seven major national and international guidelines of lipid lowering therapy. Through the lens of two clinical cases, we review physiologic changes in lipid metabolism with aging, discuss the relationship between cholesterol and cardiovascular events in older adults, examine the national and international guidelines and the available evidence informing these guidelines for statin use in primary prevention of CVD in older adults. Finally we review practical clinical considerations for drug monitoring and deprescribing in this population.
Expert Opinion:
Guidelines for the use of statins for primary CVD prevention in older adults is conflicting. Collectively, evidence to date suggests statin therapy may be beneficial for primary CVD prevention in older adults free of life-limiting comorbidities. Randomized controlled trials are currently underway to address current evidence gaps.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Alzheimer's Disease: Treatment
Cholesterol: Significance and Regulation
Considering cholesterol and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Factors Affecting Drug Response: Overview
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

